Table 2.
Yields of CIK cell expansion from PBMCs obtained from B-cell lymphoma patients
| Day 0 | Day 14 | ||||||||||||
| State | WCC (x109/L) | Blood volume (mL) | Total no of PBMCs (x106) | Total no of CD3+ cells (x106) | Seeded cells (x106) | BL-CIK | CIK | ||||||
| No of cells harvested (x106) | Fold increase | Hypothetical yield of cells (x106)* | No of cells harvested (x106) | Fold increase | Hypothetical yield of cells (x106)* | ||||||||
| Patient | |||||||||||||
| CLL1 | Relapsed | Fresh | 49.3 | 18 | 91.0 | 7.2 | 5 | 67.4 | 13.5 | 1226.7 | 32.0 | 6.4 | 582.4 |
| CLL2 | Relapsed | Fresh | 5.2 | 15 | 42.0 | 1.3 | 5 | 103.5 | 20.7 | 869.4 | 5.9 | 1.2 | 49.6 |
| CLL3 | Naïve | Fresh | 50.7 | 15 | 330.0 | 2.9 | 5 | 84.1 | 8.4 | 2775.3 | 5.5 | 1.5 | 478.5 |
| CLL4 | Naïve | Fresh | 61.2 | 18 | 420.0 | 0.8 | 5 | 29.6 | 14.8 | 6216.0 | 7.9 | 3.7 | 1541.4 |
| MCL1 | Naïve | Thawed | 336.3 | 18 | 3200.0 | 5.0 | 5 | 59.1 | 11.8 | 37 824.0 | 1.1 | 0.2 | 704.0 |
| MCL2 | Relapsed | Fresh | 23.6 | 15 | 322.0 | 2.2 | 5 | 13.7 | 2.7 | 882.3 | 3.5 | 0.7 | 225.4 |
| SMZL1 | Naïve | Thawed | 27.0 | 18 | 590.0 | 0.5 | 5 | 126.3 | 25.3 | 14 903.4 | 14.2 | 2.8 | 1675.6 |
| SMZL2 | Relapsed | Fresh | 24.1 | 18 | 300.0 | 3.3 | 5 | 33.2 | 6.6 | 1992.0 | 20.6 | 4.1 | 1236.0 |
| B-ALL | Relapsed | Fresh | 23.0 | 15 | 100.0 | 14.7 | 5 | 16.6 | 3.3 | 332.0 | 10.1 | 2.0 | 202.0 |
| Mean | 66.7 | 16.7 | 599.4 | 4.2 | 59.3 | 11.9 | 7446.8 | 11.2 | 2.5 | 743.9 | |||
| SD | 102.6 | 1.6 | 990.8 | 4.5 | 39.7 | 7.6 | 12 283.8 | 9.8 | 2.0 | 600.9 | |||
| Median | 27.0 | 18.0 | 322.0 | 2.9 | 59.1 | 11.8 | 1992.0 | 7.9 | 2.0 | 582.4 | |||
*Yield calculated considering the total number of PBMCs obtained from the sample.
B-ALL, B cell precursor acute lymphoid leukemia; CIK, cytokine induced killer; CLL1, chronic lymphocytic leukemia; MCL1, Mantle cell lymphoma; PBMCs, peripheral blood mononuclear cells; SMZL2, splenic marginal zone lymphoma; WCC, white cell count.